Aprepitant + Aprepitant Placebo + Ondansetron + Dexamethasone + Ondansetron Placebo + Rescue Therapy (granisetron, dolasetron, tropisetron or ondansetron; metoclopramide or alizapride).
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Nausea
Conditions
Nausea, Vomiting
Trial Timeline
Dec 12, 2012 → Aug 4, 2014
NCT ID
NCT01636947About Aprepitant + Aprepitant Placebo + Ondansetron + Dexamethasone + Ondansetron Placebo + Rescue Therapy (granisetron, dolasetron, tropisetron or ondansetron; metoclopramide or alizapride).
Aprepitant + Aprepitant Placebo + Ondansetron + Dexamethasone + Ondansetron Placebo + Rescue Therapy (granisetron, dolasetron, tropisetron or ondansetron; metoclopramide or alizapride). is a approved stage product being developed by Merck for Nausea. The current trial status is completed. This product is registered under clinical trial identifier NCT01636947. Target conditions include Nausea, Vomiting.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01636947 | Approved | Completed |
Competing Products
20 competing products in Nausea